Abstract: A coating agent including a polyrotaxane represented by Formula (1): wherein R1 is a hydrogen atom or a methyl group, m is 1 to 2000, and n is 10 to 500, is a cyclodextrin in which at least one hydroxyl group is modified with R2, and R2 is a C1-6 alkyl group.

Abstract: A coating agent for promoting osteoblast differentiation and/or adipocyte differentiation of mesenchymal stem cells, the coating agent comprising a polyrotaxane represented by Formula (1): wherein R1 is a hydrogen atom or a methyl group, m is 1 to 2000, and n is 10 to 500, is a cyclodextrin in which at least one hydroxyl group is modified with a group represented by —X—Y, X is a divalent organic group, and Y is a hydroxyl group or a sulfo group.

Abstract: A medicinal composition for diseases caused by dyslipidemia and/or autophagy dysfunction, etc., said medicinal composition comprising polyrotaxane that carries bulky substituents introduced, via intracellularly degradable bonds, into both ends of a linear molecule penetrating through plural cyclic molecules.

Abstract: A medicinal composition for diseases caused by dyslipidemia and/or autophagy dysfunction, etc., said medicinal composition comprising polyrotaxane that carries bulky substituents introduced, via intracellularly degradable bonds, into both ends of a linear molecule penetrating through plural cyclic molecules.

Abstract: A cell-sheet releasing agent of the present invention contains an aminated polyrotaxane. The polyrotaxane constituting the skeleton of the cell-releasing agent of the present invention has a structure in which cavities of a plurality of cyclic molecules are threaded onto a linear molecule and both terminals of the linear molecule have a bulky cap bonded thereto so that the cyclic molecules are not dethreaded from the linear molecule. Furthermore, the aminated polyrotaxane contained in the cell-releasing agent of the present invention is a compound in which at least some of hydroxy groups in the cyclodextrin structure contained in the polyrotaxane are each substituted with a substituent having an amino group. According to this cell-sheet releasing agent, cultured cells anchored to the surface of a container can be released without damaging the cells and without controlling the temperature.

Abstract: This invention relates to a myocardial pad used in cardioversion, pacing, or the like and to a myocardial lead and a therapeutic apparatus for cardiac disease comprising the same. The myocardial pad of this invention is bondable to epicardia and has conductivity, biocompatibility, and biodegradability. Using this pad, the myocardial lead can be immobilized onto the atrium without suture. Thus, bleeding from the atrium, which is a lethal complication, caused by lead removal can be prevented.

Abstract: A cell-sheet releasing agent of the present invention contains an aminated polyrotaxane. The polyrotaxane constituting the skeleton of the cell-releasing agent of the present invention has a structure in which cavities of a plurality of cyclic molecules are threaded onto a linear molecule and both terminals of the linear molecule have a bulky cap bonded thereto so that the cyclic molecules are not dethreaded from the linear molecule. Furthermore, the aminated polyrotaxane contained in the cell-releasing agent of the present invention is a compound in which at least some of hydroxy groups in the cyclodextrin structure contained in the polyrotaxane are each substituted with a substituent having an amino group. According to this cell-sheet releasing agent, cultured cells anchored to the surface of a container can be released without damaging the cells and without controlling the temperature.

Abstract: This invention provides to a novel pharmaceutical preparation for the treatment of gynecological diseases. The pharmaceutical preparation according to the invention comprises a therapeutic drug for the intrauterine, intravaginal or intrapelvic administration, or for the administration into the ovarian endometrioma, and a biodegradable polymer comprising a chemically modified hyaluronic acid or a salt thereof prepared by O-acylating, alkoxylating or crosslinking a complex of hyaluronic acid or a salt thereof and a cationic compound in a nonaqueous solvent. The preparation of the invention is preferably administered intrauterine, intravaginal, intrapelvic, and intratumor cavity.

Abstract: A drug is provided comprising of a degradable gel with a saturated moisture content not exceeding 98 wt. % and a functional material, and which permits control of the rate of release of the functional material and performs controlled-release of the functional material over a prolonged period of time, and wherein the gel itself decomposes and dissipates upon completion of release of the functional material.

Abstract: To provide degradable gel hardly degradable and having enough strength, and a method for producing the same.

Abstract: A multivalently interactive molecular assembly having a plurality of functional groups or ligands, in which a ratio between Rh and Rg expressed as Rh/Rg is 1.0 or less. Here, Rh is a hydrodynamic radius calculated from dynamic light scattering (DLS) assay performed in aqueous solution; and Rg is a radius of gyration determined based on the Zimm plot generated using data obtained by static light scattering (SLS) assay.

Abstract: This invention relates to a chemically modified hyaluronic acid and salts thereof, which are obtained by O-acylating, alkoxylating or crosslinking a complex consisting of hyaluronic acid or a salt thereof and a cationic compound in a nonaqueous solvent, and a process for the production thereof. The nonaqueous solvent used in the invention is preferably one or more solvents selected from the group consisting of chloroform, toluene, methylene chloride and heptane.

Abstract: A multivalently interactive molecular assembly having a plurality of functional groups or ligands, in which a ratio between Rh and Rg expressed as Rh/Rg is 1.0 or less. Here, Rh is a hydrodynamic radius calculated from dynamic light scattering (DLS) assay performed in aqueous solution; and Rg is a radius of gyration determined based on the Zimm plot generated using data obtained by static light scattering (SLS) assay.

Abstract: Base materials for tissue regeneration which enable the tissue regeneration, have mechanical properties needed in the tissue regeneration and can disappear via degradation in vivo after the completion of the tissue regeneration; and implantable materials with the use of the same. The above-described base materials for tissue regeneration comprise polyrotaxane, wherein biocompatible groups having bulky substituents have been introduced via hydrolyzable bond into both ends of a linear molecule penetrating plural cyclic molecules, or a polyrotaxane hydrogel having a network structure formed by crosslinking the cyclic molecules to each other, the biocompatible groups to each other, or the cyclic molecules to the biocompatible groups in each polyrotaxane molecule.

Abstract: This invention provides to a novel pharmaceutical preparation for the treatment of gynecological diseases. The pharmaceutical preparation according to the invention comprises a therapeutic drug for the intrauterine, intravaginal or intrapelvic administration, or for the administration into the ovarian endometrioma, and a biodegradable polymer comprising a chemically modified hyaluronic acid or a salt thereof prepared by O-acylating, alkoxylating or crosslinking a complex of hyaluronic acid or a salt thereof and a cationic compound in a nonaqueous solvent. The preparation of the invention is preferably administered intrauterine, intravaginal, intrapelvic, and intratumor cavity.

Abstract: This invention relates to a chemically modified hyaluronic acid and salts thereof, which are obtained by O-acylating, alkoxylating or crosslinking a complex consisting of hyaluronic acid or a salt thereof and a cationic compound in a nonaqueous solvent, and a process for the production thereof. The nonaqueous solvent used in the invention is preferably one or more solvents selected from the group consisting of chloroform, toluene, methylene chloride and heptane.

Abstract: A platelet metabolism suppressing blood compatible material has a supramolecular structure containing a plurality of cyclic compounds and a hydrophilic straight-chain polymer threading into cavities of the cyclic compounds. Both terminals of the polymer are respectively capped with biodegradable groups having bulks sufficient to prevent the dethreading of the cyclic compounds.

Abstract: An antithrombogenic synthetic polymer has repeat structural units represented by the following structural formula consisting of portions I and II: ##STR1## a microdomain structure composed of crystalline phases and amorphous phases, each phase having an average size of 5 to 10 nm, and a molecular weight in the range of about 10,000 to about 300,000. The polymer exhibits little adhesion of blood platelets thereto, an excellent antithrombogenic property and a sufficient mechanical strength.

Abstract: Antithrombogenic synthetic elastomer having repeat units comprising portion I which is a soft segment unit containing a polyether and portion II which is a hard segment unit: ##STR1## R is a straight-chain or branched-chain alkylene group containing 2 to 4 carbon atoms, R' is amide a urethane, an urea, n ranges up to 180, m is an integer of 1 to 20, l is an integer of 1 to 10, said polymer having a microdomain structure composed of soft and hard segments, the domains of which have an average size of 10 to 20 nm, and a molecular weight of about 80,000 to about 500,000.The polymer shows little adhesion of blood platelets thereto, little deformation of adhering blood platelets and an excellent antithrombogenic property. This polymer has excellent mechanical properties as an elastomer.